Skip to content
Clinical Trials – home

Rheumazentrum Greifswald

Verified siteinfo

Germany Rheumazentrum Greifswald Rigaer Str. 9 17493 Greifswald, 17493 Greifswald, Germany

  • 1 trial recruiting
  • Sjogren's syndrome · Systemic lupus erythematosus
  • Adults and children

About Specializations

Rheumazentrum Greifswald in Greifswald, Germany specialises in clinical trials of conditions such as Sjogren's syndrome, Systemic lupus erythematosus, and other specialisations. This site conducts important research.

Main research areas of the site

Rheumatology and Autoimmune Diseases

The medical center is at the forefront of research in rheumatology and autoimmune diseases, with a particular focus on systemic lupus erythematosus (SLE). The center's research aims to enhance the understanding and treatment of these complex conditions.

  • Systemic Lupus Erythematosus (SLE)
  • Autoimmune Disease Management
  • Innovative Therapeutic Approaches

Through ongoing studies, the center is exploring the efficacy and safety of novel treatments like dapirolizumab pegol as an add-on to standard care, aiming to achieve significant long-term improvements in disease activity for patients with moderate to severe SLE.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Rheumazentrum Greifswald Rigaer Str. 9 17493 Greifswald17493 GreifswaldGermany
Recruiting now
1 trial
Conditions studied
2
Partner status
Verified site

More sites in GreifswaldGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

4 clinical trials

Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:UCB Biopharma

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Amgen Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.